Furthermore, since endothelial cells have been demonstrated to be the principal source of type I IFNs in growing tumors and endothelial cell-derived IFNβ initiates CD8+ T cell-mediated anti-tumor immunity48,49, the contribution of IFNβ produced by cancer cells to T cell priming may be minimal. This evidence concerns the gene IFNB1 and cancer.